Leigh Farrell
Plus aucun poste en cours
Historique de carrière de Leigh Farrell
Anciens postes connus de Leigh Farrell
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Corporate Officer/Principal | - | - |
| Johnson & Johnson Research Pty Ltd. | Directeur Technique/Scientifique/R&D | 15/02/2011 | - |
| Corporate Officer/Principal | - | 15/02/2011 | |
| Gene Shears Pty Ltd. | President | - | - |
| BIOTA HOLDINGS LTD. | Corporate Officer/Principal | 28/07/2009 | - |
Statistiques
Internationale
| Australie | 4 |
| Etats-Unis | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| President | 1 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Biota Holdings Pty Ltd.
 Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
| Johnson & Johnson Research Pty Ltd. | |
| Gene Shears Pty Ltd. | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Bourse
- Insiders
- Leigh Farrell
- Expérience
